Zie de multidicsiplinaire Richtlijn ICD/pacemaker in de laatste levensfase. 127
ICD
Een functionerende implanteerbare cardioverter-defibrillator (ICD) kan het overlijdensproces verstoren door het afgeven van shocks en moet daarom worden gedeactiveerd in de palliatieve fase of bij euthanasie. Deactivering geeft geen toename van cardiale klachten.
Reguliere deactivering van de ICD vindt plaats in het ziekenhuis. Indien de patiënt niet meer in staat is om naar het ziekenhuis te komen, kan deactivering alleen nog plaatsvinden via een noodprocedure waarbij een ziekenhuismedewerker ter plaatse de ICD komt deactiveren. Dit kan echter veelal niet direct plaatsvinden.
Bij spoed kan een sterke magneet op de huid ter plaatse van de ICD worden gelegd (eventueel te fixeren met tape). Zolang deze aanwezig is, is de ICD-functie gedeactiveerd. Een dergelijke magneet is aanwezig in een ambulance en in sommige regio’s ook in de auto’s van de
huisartsenpost.
Pacemaker
Deactivering van een pacemaker kan toename van cardiale klachten geven en is daarom niet wenselijk.
Een functionerende pacemaker zal het overlijdensproces niet verstoren en is belangrijk voor het comfort van de patiënt.
Referenties
Nielen MM, Hek K, Schermer TR. Jaarcijfers aandoeningen: incidenties en prevalenties. Utrecht: NIVEL, 2020. 1.
www.nivel.nl/nl/nivel-zorgregistraties-eerste-lijn, geraadpleegd 20 oktober 2020. Ga naar bron: Nielen MM, Hek K, Schermer TR. Jaarcijfers aandoeningen: incidenties en prevalenties. Utrecht: NIVEL, 2020.
www.nivel.nl/nl/nivel-zorgregistraties-eerste-lijn, geraadpleegd 20 oktober 2020.
Hartstichting. Hart- en vaatziekten in Nederland 2018: cijfers over risicofactoren, hartinterventies, ziekte en sterfte. 2.
Den Haag: Hartstichting, 2018. www.hartstichting.nl , geraadpleegd oktober 2020.
Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, 3.
lifetime risk and prognosis of heart failure: The Rotterdam Study. Eur Heart J 2004;25:1614-9.
Van Riet EE, Hoes AW, Limburg A, Landman MA, Kemperman H, Rutten FH. Extended prediction rule to optimise 4.
early detection of heart failure in older persons with non-acute shortness of breath: a cross-sectional study. BMJ Open 2016;6:e008225.
Brouwers FP, De Boer RA, Van der Harst P, et al. Incidence and epidemiology of new onset heart failure with 5.
preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 2013;34:1424-31.
ESC. Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: Addenda. European Society 6.
of Cardiology, 2012. www.escardio.org, geraadpleegd oktober 2020. Ga naar bron: ESC. Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: Addenda. European Society of Cardiology, 2012.
www.escardio.org, geraadpleegd oktober 2020.
Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital 7.
outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006;47:76-84. Rutten FH, Grobbee DE, Hoes AW. Differences between general practitioners and cardiologists in diagnosis and 8.
management of heart failure: a survey in every-day practice. Eur J Heart Fail 2003;5:337-44.
Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. Lancet 2019;393:1034-44. 9.
Lindenfeld J, Krause-Steinrauf H, Salerno J. Where are all the women with heart failure? J Am Coll Cardiol 10.
1997;30:1417-9.
Burch D. Heart failure: gaps in knowledge and failures in treatment. PLoS Med 2014;11:e1001702. 11.
Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic 12.
obstructive pulmonary disease. Eur Heart J 2005a;26:1887-94.
Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left 13.
ventricular dysfunction in patients with type 2 diabetes. Diabetologia 2012;55:2154-62.
Van Riet EE, Hoes AW, Limburg A, Landman MA, Van der Hoeven H, Rutten FH. Prevalence of unrecognized heart 14.
failure in older persons with shortness of breath on exertion. Eur J Heart Fail 2014;16:772-7.
Van Mourik Y, Bertens LC, Cramer MH, et al. Unrecognized heart failure and chronic obstructive pulmonary disease 15.
(COPD) in frail elderly detected through a near-home targeted screening strategy. J Am Board Fam Med 2014;27:811-21.
Ponikowski P, Voors AA, Anker SD; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and 16.
treatment of acute and chronic heart failure. European Society Cardiology. Eur Heart J 2016;37:2129-200. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men 17.
and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001;161:996-1002.
Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994;72:S3-9. 18.
Bibbins-Domingo K, Pletcher MJ, Lin F, Vittinghoff E, Gardin JM, Arynchyn A, Lewis CE, Williams OD, Hulley SB. 19.
Racial differences in incident heart failure among young adults. N Engl J Med 2009 Mar 19;360:1179-90. Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart 20.
failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1574-85.
Maggioni AP, Dahlström U, Filippatos G, et al. EURObservational Research Programme: regional differences and 1-21.
year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013;15:808-17.
Rutten FH, Cramer MJ, Paulus WJ. Hartfalen met gepreserveerde ejectiefractie: diastolisch hartfalen. Ned Tijdschr 22.
Geneeskd 2012b;156:A5315.
Meijers WC, Van der Velde AR, Muller Kobold AC, et al. Variability of biomarkers in patients with chronic heart failure 23.
and healthy controls. Eur J Heart Fail 2017;19:357-65.
Van Kimmenade R, Van Dielen F, Bakker J, et al. Is brain natriuretic peptide production decreased in obese subjects? J 24.
Am Coll Cardiol 2006;47:886-7.
Suthahar N, Meijers WC, Ho JE, et al. Sex-specific associations of obesity and N-terminal pro-B-type natriuretic 25.
peptide levels in the general population. Eur J Heart Fail 2018;20:1205-14.
Mueller C, Laule-Kilian K, Scholer A, et al. Use of B-type natriuretic peptide for the management of women with 26.
NHG-Standaard Hartfalen - pagina 119
Kelder JC, Cramer MJ, Van Wijngaarden J, et al. The diagnostic value of physical examination and additional testing in 27.
primary care patients with suspected heart failure. Circulation 2011;124:2865-73.
NICE. Guideline Chronic heart failure in adults: Diagnosis and management (NG106). London: National Institute for 28.
Health and Care Excellence 2018. https://www.nice.org.uk/guidance/ng106, geraadpleegd oktober 2020. Ga naar bron: NICE. Guideline Chronic heart failure in adults: Diagnosis and management (NG106). London: National Institute for Health and Care Excellence 2018. https://www.nice.org.uk/guidance/ng106, geraadpleegd oktober 2020.
Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new 29.
heart failure in primary care. Lancet 1997;350:1349-53.
Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating 30.
between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 2004;6:63-70.
Zaphiriou A, Robb S, Murray-Thomas T, et al. The diagnostic accuracy of plasma BNP and NT-pro-BNP in patients 31.
referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 2005;7:537-41.
Zuber M, Cuculi F, Attenhofer et al. Value of brain natriuretic peptides in primary care patients with the clinical 32.
diagnosis of chronic heart failure. Scand Cardiovasc J 2009;43:324-9.
O'Shea P, Daly R, Kasim S, Tormey WP. B-type natriuretic peptide in the cardiology department. Ir Med J 33.
2012;105:341-3.
Verdú JM, Comín-Colet J, Domingo M, et al. Rapid point-of-care NT-pro-BNP optimal cut-off point for heart failure 34.
diagnosis in primary care. Rev Esp Cardiol (Engl Ed) 2012;65:613-9.
Taylor CJ, Roalfe AK, Iles R, et al.; REFER investigators. Primary care REFerral for EchocaRdiogram (REFER) in heart 35.
failure: a diagnostic accuracy study. Br J Gen Pract 2017b;67:e94-102.
Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart 36.
failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009;13:32.
Gallagher J, McCormack D, Zhou S, et al. A systematic review of clinical prediction rules for the diagnosis of chronic 37.
heart failure. ESC Heart Fail 2019;6:499-508.
Kievit RF, Gohar A, Hoes AW, et al; Queen of Hearts and RECONNECT consortium. Efficient selective screening for 38.
heart failure in elderly men and women from the community: A diagnostic individual participant data meta-analysis. Eur J Prev Cardiol 2018;25:437-46.
Taylor CJ, Monahan M, Roalfe AK, Barton P, Iles R, Hobbs FD. The REFER (REFer for EchocaRdiogram) study: a 39.
prospective validation and health economic analysis of a clinical decision rule, NT-pro-BNP or their combination in the diagnosis of heart failure in primary care. Southampton (UK): NIHR Journals Library, 2017a.
Monahan M, Barton P, Taylor CJ, et al.; REFER investigators. MICE or NICE? An economic evaluation of clinical 40.
decision rules in the diagnosis of heart failure in primary care. Int J Cardiol 2017;241:255-61.
Smeets M, Degryse J, Janssens S, et al. Diagnostic rules and algorithms for the diagnosis of non-acute heart failure in 41.
patients 80 years of age and older: a diagnostic accuracy and validation study. BMJ Open 2016;6:e012888.
Tait L, Roalfe AK, Mant J, et al. The REFER (REFer for EchocaRdiogram) protocol: a prospective validation of a clinical 42.
decision rule, NT-pro-BNP, or their combination, in the diagnosis of heart failure in primary care. Rationale and design. BMC Cardiovasc Disord 2012;12:97.
Roalfe AK, Mant J, Doust JA, et al. Development and initial validation of a simple clinical decision tool to predict the 43.
presence of heart failure in primary care: the MICE (Male, Infarction, Crepitations, Edema) rule. Eur J Heart Fail 2012;14:1000-8.
Rutten FH, Walma EP, Kruizinga GI, Bakx HCA, Van Lieshout J. NHG-Standaard Hartfalen, eerste herziening. Huisarts 44.
Wet 2005b;48:64-77. www.henw.org, geraadpleegd oktober 2020. Ga naar bron: Rutten FH, Walma EP, Kruizinga GI, Bakx HCA, Van Lieshout J. NHG-Standaard Hartfalen, eerste herziening. Huisarts Wet 2005b;48:64-77.
www.henw.org, geraadpleegd oktober 2020.
Oudejans I, Mosterd A, Bloemen JA, et al. Clinical evaluation of geriatric outpatients with suspected heart failure: 45.
value of symptoms, signs, and additional tests. Eur J Heart Fail 2011;13:518-27.
Fahey T, Jeyaseelan S, McCowan C, et al. Diagnosis of left ventricular systolic dysfunction (LVSD): development and 46.
validation of a clinical prediction rule in primary care. Fam Pract 2007;24:628-35.
Nielsen OW, Hansen JF, Hilden J, Larsen CT, Svanegaard J. Risk assessment of left ventricular systolic dysfunction in 47.
primary care: cross sectional study evaluating a range of diagnostic tests. BMJ 2000;320:220-4.
NICE. Guideline Chronic heart failure in adults: Diagnosis and management (CG108). London: National Institute for 48.
Health and Care Excellence 2010. www.nice.org.uk Ga naar bron: NICE. Guideline Chronic heart failure in adults: Diagnosis and management (CG108). London: National Institute for Health and Care Excellence 2010.
www.nice.org.uk
Badgett RG, Mulrow CD, Otto PM, Ramirez G. How well can the chest radiograph diagnose left ventricular 49.
dysfunction? J Gen Intern Med 1996;11:625-34.
Krueger K, Botermann L, Schorr SG, Griese-Mammen N, Laufs U, Schulz M. Age-related medication adherence in 50.
patients with chronic heart failure: A systematic literature review. Int J Cardiol 2015;184:728-35.
Riegel B. I Forgot: Memory and Medication Adherence in Heart Failure. Circ Heart Fail. 2016 Dec;9:e003642. 51.
Ekman I, Cleland JG, Swedberg K, Charlesworth A, Metra M, Poole-Wilson PA. Symptoms in patients with heart failure 52.
are prognostic predictors: insights from COMET. J Card Fail 2005;11:288-92.
Patel H, Shafazand M, Schaufelberger M, Ekman I. Reasons for seeking acute care in chronic heart failure. Eur J Heart 53.
Fail. 2007;9:702-8.
Lewin J, Ledwidge M, O'Loughlin C, McNally C, McDonald K. Clinical deterioration in established heart failure: what is 54.
the value of BNP and weight gain in aiding diagnosis? Eur J Heart Fail 2005;7:953-7.
Jonkman NH, Westland H, Groenwold RH, et al. Do self-management interventions work in patients with heart failure? 55.
An individual patient data meta-analysis. Circulation 2016;133:1189-98.
Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus 56.
Conference). Am J Cardiol 2005;96:85M-93M.
NVVC. Multidisciplinaire richtlijn Hartrevalidatie. Utrecht: Nederlandse Vereniging voor Cardiologie, 2011. 57.
www.nvvc.nl, geraadpleegd oktober 2020. Ga naar bron: NVVC. Multidisciplinaire richtlijn Hartrevalidatie. Utrecht: Nederlandse Vereniging voor Cardiologie, 2011. www.nvvc.nl, geraadpleegd oktober 2020.
Flynn KE, Pina IL, Whellan DJ, et al. Effects of exercise training on health status in patients with chronic heart failure: 58.
HF-ACTION randomized controlled trial. JAMA 2009;301:1451-9.
O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: 59.
HF-ACTION randomized controlled trial. JAMA 2009;301:1439-50.
Whellan DJ, O'Connor CM, Lee KL, et al. Heart failure and a controlled trial investigating outcomes of exercise 60.
training (HF-ACTION): design and rationale. Am Heart J 2007;153:201-11.
Long L, Mordi IR, Bridges C. et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane 61.
Database Syst Rev 2019;1:CD003331.
Cederholm T, Jensen GL, Correia MITD, et al.; GLIM Core Leadership Committee, GLIM Working Group. GLIM criteria 62.
for the diagnosis of malnutrition - a consensus report from the global clinical nutrition community. J Cachexia Sarcopenia Muscle 2019;10:207-17.
Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. 63.
Lancet 1997;349:1050-3.
Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of 64.
treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077-83. Springer J, Filippatos G, Akashi YJ, Anker SD. Prognosis and therapy approaches of cardiac cachexia. Curr Opin 65.
Cardiol 2006;21:229-33.
Von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic 66.
heart failure. Cardiovasc Res 2007;73:298-309.
Alpert MA, Terry BE, Mulekar M, et al. Cardiac morphology and left ventricular function in normotensive morbidly 67.
obese patients with and without congestive heart failure, and effect of weight loss. Am J Cardiol 1997;80:736-40. Mariotti R, Castrogiovanni F, Canale ML, Borelli G, Rondinini L. Weight loss and quality of life in chronic heart failure 68.
patients. J Cardiovasc Med (Hagerstown) 2008;9:576-80.
Nicklas BJ, Cesari M, Penninx BW, et al. Abdominal obesity is an independent risk factor for chronic heart failure in 69.
older people. J Am Geriatr Soc 2006;54:413-20.
Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the 70.
prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation 2017;135:e867-84.
Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF 71.
trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-9.
Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 72.
2014;370:1383-92.
Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved 73.
Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015;131:34-42. Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in 74.
patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013;309:781-91.
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the 75.
Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with 76.
reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-77.
converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-8.
CIBIS-II. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13. 78.
MERIT-HF. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in 79.
Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart 80.
NHG-Standaard Hartfalen - pagina 121
failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9.
Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, 81.
hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295-302.
Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and 82.
cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25. Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol 83.
Heart Failure Study Group. J Card Fail 1997;3:173-9.
Packer M, Coats AJ, Fowler MB, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of 84.
carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-8.
Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW. A trial of the beta-blocker bucindolol in 85.
patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in 86.
patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
Bangalore S, Kumar S , Messerli, FH. When conventional heart failure therapy is not enough: angiotensin receptor 87.
blocker, direct renin inhibitor, or aldosterone antagonist? Congest Heart Fail 2013;19:107-15.
KNMP. Kennisbank. Den Haag: Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie, 2020. 88.
www.knmp.nl, geraadpleegd oktober 2020. Ga naar bron: KNMP. Kennisbank. Den Haag: Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie, 2020. www.knmp.nl, geraadpleegd oktober 2020.
Santema BT, Ouwerkerk W, Tromp J, et al. Identifying optimal doses of heart failure medications in men compared 89.
with women: a prospective, observational, cohort study. Lancet 2019;394:1254-63.
Dixon DW, Barwolf-Gohlke C, Gunnar RM. Comparative efficacy and safety of bumetanide and furosemide in long‐term 90.
treatment of edema due to congestive heart failure. J Clin Pharmacol 1981;21:680-7.
Konecke LL. Clinical trial of bumetanide versus furosemide in patients with congestive heart failure. J Clin Pharmacol 91.
1981;21:688-90.
Fitchett D, Butler J, Van de Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure 92.
hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial. Eur Heart J 2018;39:363-70.
Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes 93.
mellitus. Circulation 2019;139:2528-36.
Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the 94.
CANVAS program. Circulation 2018;138:458-68.
Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at 95.
high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 2016;37:1526-34.
Butler J, Zannad F, Fitchett D, et al. empagliflozin improves kidney outcomes in patients with or without heart failure. 96.
Circ Heart Fail 2019;12:e005875.
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection 97.
fraction. N Engl J Med 2019;381:1995-2008.
Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in 98.
patients with heart failure with and without diabetes JAMA 2020;323:1353-68.
Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and 99.
renal events in type 2 diabetes. N Engl J Med 2017;377:644-57.
Wiviott SD, Raz I, Bonaca MP, et al; DECLARE–TIMI 58 Investigators. dapagliflozin and cardiovascular outcomes in 100.
type 2 diabetes. N Engl J Med 2019;380:347-57.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N 101.
Engl J Med 2015;373:2117-28.
Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-102.
glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med 2019;170:764-9. Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients 103.
with heart failure with reduced ejection fraction: the DEFINE-HF Trial. Circulation 2019;140:1463-76.
Packer M, Anker SD, Butler J, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with 104.
empagliflozin in heart failure. N Engl J Med 2020;383:1413-24.
Wesseling E. ARNi's: nieuwe medicatie bij hartfalen? Huisarts Wet 2015;58:446. 105.
McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J 106.
Med 2014;371:993-1004.
Edwards SJ, Crawford F, Osei-Assibey G, Bacelar M, Berardi A, Salih F. Sacubitril valsartan for treating chronic heart 107.
failure: a single technology appraisal. London: BMJ Technology Assessment Group, 2015.
Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised 108.
Bohm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association 109.
between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010;376:886-94.